I am unable to access the specific article from The Wall Street Journal regarding Bylvay missing its primary objective in a study, as the provided URL leads to a paywalled or unavailable page. Therefore, I cannot provide a summary based on that specific content.
However, information from other sources indicates that Bylvay (odevixibat) has shown positive results in clinical trials for conditions like Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). For instance, Bylvay received U.S. FDA approval for cholestatic pruritus due to Alagille syndrome in May 2023. This approval was supported by data from the Phase III ASSERT study, which demonstrated statistically significant and sustained improvements in pruritus (itching) and reductions in serum bile acid levels.
The ASSERT study showed that more than 90% of patients were considered pruritus responders, experiencing at least a one-point change in their scratching score during the 24-week trial. Significant improvements in sleep parameters were also observed as early as one week into treatment. The adverse event incidence was similar to placebo, and no patients discontinued the study, with 96% rolling over into an open-label extension. Longer-term data up to 72 weeks also indicated sustained improvements in pruritus and serum bile acid levels, with most adverse events being mild to moderate and gastrointestinal issues like diarrhea being the most common (17.2%).
These results suggest that Bylvay is effective in managing key symptoms of these cholestatic liver diseases. The drug's efficacy in reducing pruritus and bile acid levels, coupled with a manageable safety profile, has led to regulatory approvals and positive assessments in clinical and scientific communities. globenewswire.com, ipsen.com, ipsen.com, ipsen.com
